These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33470563)

  • 1. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.
    McGarry ME; McColley SA
    Pediatr Pulmonol; 2021 Jun; 56(6):1496-1503. PubMed ID: 33470563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.
    McGarry ME; Gibb ER; Oates GR; Schechter MS
    Paediatr Respir Rev; 2022 Jun; 42():35-42. PubMed ID: 35277357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies.
    Desai M; Hine C; Whitehouse JL; Brownlee K; Charman SC; Nagakumar P
    Respir Med; 2022 Aug; 199():106878. PubMed ID: 35633605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of disease-causing CFTR variants in state newborn screening programs.
    McGarry ME; Ren CL; Wu R; Farrell PM; McColley SA
    Pediatr Pulmonol; 2023 Feb; 58(2):465-474. PubMed ID: 36237137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.
    Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E
    J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic Fibrosis: Highly Effective Targeted Therapeutics and the Impact on Sex and Racial Disparities.
    Montemayor K; Jain R
    Med Clin North Am; 2022 Nov; 106(6):1001-1012. PubMed ID: 36280328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators.
    Colombo C; Ramm GA; Lindblad A; Corti F; Porcaro L; Alghisi F; Asherova I; Evans H; Kashirskaya N; Kondratyeva E; Lewindon PJ; de Monestrol I; Oliver M; Ooi CY; Padoan R; Shankar S; Alicandro G
    J Cyst Fibros; 2023 Mar; 22(2):263-265. PubMed ID: 36739240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies.
    Bresnick K; Arteaga-Solis E; Millar SJ; Laird G; LeCamus C
    BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34857524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
    Burgener EB; Moss RB
    Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.
    de Poel E; Spelier S; Hagemeijer MC; van Mourik P; Suen SWF; Vonk AM; Brunsveld JE; Ithakisiou GN; Kruisselbrink E; Oppelaar H; Berkers G; de Winter de Groot KM; Heida-Michel S; Jans SR; van Panhuis H; Bakker M; van der Meer R; Roukema J; Dompeling E; Weersink EJM; Koppelman GH; Blaazer AR; Muijlwijk-Koezen JE; van der Ent CK; Beekman JM
    J Cyst Fibros; 2023 May; 22(3):548-559. PubMed ID: 37147251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
    Derichs N
    Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy.
    Farley H; Poole S; Chapman S; Flight W
    Postgrad Med J; 2022 May; 98(1159):341-345. PubMed ID: 33452147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global disparities in cystic fibrosis outcomes prior to CFTR modulators: A CF registries cohort study in South Africa and Canada.
    Zampoli M; Sykes J; Verstraete J; Cheng SY; Morrow B; Pepper MS; Stewart C; Zar HJ; Stephenson AL
    J Cyst Fibros; 2024 Mar; 23(2):334-340. PubMed ID: 37704465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.
    Sawicki GS; Van Brunt K; Booth J; Bailey E; Millar SJ; Konstan MW; Flume PA
    J Cyst Fibros; 2022 Jan; 21(1):96-103. PubMed ID: 34289939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.